Advances in hepatic arterial infusion chemotherapy for colorectal liver metastases

Abstract

Abstract: Approximately 50% of patients with colorectal cancer (CRC) develop liver metastases during the course of their disease. Liver metastases have become a key determinant of long-term prognosis in patients with CRC, and multiple studies have demonstrated the poor prognosis of patients with colorectal cancer liver metastases (CRLM). In recent years, hepatic arterial infusion chemotherapy (HAIC) has been recommended by multiple Chinese and international guidelines in treating CRLM. In addition, several prospective phase Ⅱ/Ⅲ clinical trials and retrospective studies with large sample size have demonstrated the efficacy and safety of HAIC, either alone or in combination with systemic therapy, for patients with CRLM. Based on the available literature and clinical experience, this review summarizes recent advances in HAIC for CRLM, including technical essentials, drug selection, and its clinical value as adjuvant therapy for resectable liver metastases, conversion therapy for initially unresectable liver metastases, first-line therapy for advanced unresectable liver metastases, and salvage therapy. This review aims to provide a practical reference for the clinical application of HAIC in treating CRLM.

Key words: Colorectal cancer liver metastases, Hepatic arterial infusion chemotherapy, Clinical application, Research progress

Fan Xiaoyu, Zheng Kanglian, Wang Xiaodong. Advances in hepatic arterial infusion chemotherapy for colorectal liver metastases[J]. Electronic Journal of Liver Tumor, 2026, 13(3): 40-50.

References

[1] Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Vibert E, Canedo L, Adam R.Strategies to treat primary unresectable colorectal liver metastases[J]. Semin Oncol, 2005, 32(6 Suppl 8): 33-39.
[3] Abbas S, Lam V, Hollands M.Ten-year survival after liver resection for colorectal metastases: systematic review and Meta-analysis[J]. ISRN Oncol, 2011, 2011: 763245.
[4] Kwan J, Pua U.Review of intra-arterial therapies for colorectal cancer liver metastasis[J]. Cancers (Basel), 2021, 13(6): 1371.
[5] Zheng K, Wang X.Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers[J]. Ther Adv Med Oncol, 2024, 16: 17588359231225040.
[6] Seki H, Shiina M.Placement of a long tapered side-hole catheter in the hepatic artery: technical advantages, catheter stability, and arterial patency[J]. AJR Am J Roentgenol, 2006, 187(5): 1312-1320.
[7] Arai Y, Takeuchi Y, Inaba Y, et al.Percutaneous catheter placement for hepatic arterial infusion chemotherapy[J]. Tech Vasc Interv Radiol, 2007, 10(1): 30-37.
[8] Hu J, Zhu X, Wang X, et al.Evaluation of percutaneous unilateral trans-femoral implantation of side-hole port-catheter system with coil only fixed-catheter-tip for hepatic arterial infusion chemotherapy[J]. Cancer Imaging, 2019, 19(1): 15.
[9] Seki H, Kimura M, Yoshimura N, et al.Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery[J]. Clin Radiol, 1999, 54(4): 221-227.
[10] Irie T.Intraarterial chemotherapy of liver metastases: implantation of a microcatheter-port system with use of modified fixed catheter tip technique[J]. J Vasc Interv Radiol, 2001, 12(10): 1215-1218.
[11] Thiels CA, D'angelica MI. Hepatic artery infusion pumps[J]. J Surg Oncol, 2020, 122(1): 70-77.
[12] 朱德祥,任黎. 结直肠癌肝转移诊断和综合治疗指南(2025版)[J]. 中国普通外科杂志,2025,34(8):1565-1588.
[13] Benson AB, Venook AP, Adam M, et al.Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(2D): e240029.
[14] Benson AB, Venook AP, Adam M, et al.NCCN guidelines(R) insights: rectal cancer, version 3.2024[J]. J Natl Compr Canc Netw, 2024, 22(6): 366-375.
[15] Kemeny NE, Niedzwiecki D, Hollis DR, et al.Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)[J]. J Clin Oncol, 2006, 24(9): 1395-403.
[16] Mocellin S, Pilati P, Lise M, et al.Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?[J]. J Clin Oncol, 2007, 25(35): 5649-5654.
[17] Hallet J, Sa Cunha A, Adam R, et al.Factors influencing recurrence following initial hepatectomy for colorectal liver metastases[J]. Br J Surg, 2016, 103(10): 1366-1376.
[18] Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver[J]. Cochrane Database Syst Rev, 2006, 2006(4): CD003770.
[19] Buisman FE, Filipe WF, Galjart B, et al.Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and Meta-analysis[J]. HPB (Oxford), 2022, 24(3): 299-308.
[20] Outmani L, Buisman F, Filipe W F, et al. Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: a randomized controlled trial—The PUMP trial[J]. J Clin Oncol, 2026, 44(17 Suppl): LBA3506.
[21] Kemeny N, Huang Y, Cohen AM, et al.Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer[J]. N Engl J Med, 1999, 341(27): 2039-2048.
[22] Kemeny NE, Gonen M.Hepatic arterial infusion after liver resection[J]. N Engl J Med, 2005, 352(7): 734-735.
[23] Kemeny N, Capanu M, D'angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer[J]. Ann Oncol, 2009, 20(7): 1236-1241.
[24] Alberts SR, Roh MS, Mahoney MR, et al.Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase Ⅱ intergroup trial, N9945/CI-66[J]. J Clin Oncol, 2010, 28(5): 853-858.
[25] Koerkamp BG, Sadot E, Kemeny NE, et al.Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis[J]. J Clin Oncol, 2017, 35(17): 1938-1944.
[26] Wang DS, Pat Fong W, Wen L, et al.Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): a randomized controlled trial[J]. Eur J Cancer, 2025, 214: 115154.
[27] Nordlinger B, Sorbye H, Glimelius B, et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial[J]. Lancet, 2008, 371(9617): 1007-1016.
[28] Goere D, Benhaim L, Bonnet S, et al.Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy[J]. Ann Surg, 2013, 257(1): 114-120.
[29] Gelli M, Ewald J, Tanguy ML, et al.Postoperative hepatic arterial infusion with oxaliplatin after surgery of four or more colorectal liver metastases: a randomized phase Ⅱ trial[J]. J Clin Oncol, 2026, 44(15): 1416-1429.
[30] Gholami S, Kemeny NE, Boucher TM, et al.Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of kras mutation status in patients with resected colorectal liver metastases: a retrospective analysis of 674 patients[J]. Ann Surg, 2020, 272(2): 352-356.
[31] Gholami S, Stewart S, Kemeny N, et al.Impact of primary tumor laterality on adjuvant hepatic artery infusion pump chemotherapy in resected colon cancer liver metastases: analysis of 487 patients[J]. Ann Surg Oncol, 2021, 28(7): 3685-3694.
[32] Kemeny N, Gonen M, Sullivan D, et al.PhaseⅠstudy of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer[J]. J Clin Oncol, 2001, 19(10): 2687-2695.
[33] Kemeny N, Jarnagin W, Paty P, et al.Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer[J]. J Clin Oncol, 2005, 23(22): 4888-4896.
[34] Kemeny NE, Melendez FD, Capanu M, et al.Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma[J]. J Clin Oncol, 2009, 27(21): 3465-3471.
[35] Pak LM, Kemeny NE, Capanu M, et al.Prospective phaseⅡ trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential[J]. J Surg Oncol, 2018, 117(4): 634-643.
[36] D'angelica MI, Correa-Gallego C, Paty PB, et al. PhaseⅡ trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes[J]. Ann Surg, 2015, 261(2): 353-360.
[37] Verheij FS, Kuhlmann KFD, Silliman DR, et al.Combined hepatic arterial infusion pump and systemic chemotherapy in the modern era for chemotherapy-naive patients with unresectable colorectal liver metastases[J]. Ann Surg Oncol, 2023, 30(13): 7950-7959.
[38] Goere D, Deshaies I, De Baere T, et al.Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases[J]. Ann Surg, 2010, 251(4): 686-691.
[39] Levi FA, Boige V, Hebbar M, et al.Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV[J]. Ann Oncol, 2016, 27(2): 267-274.
[40] Levi F, Ducreux M, Smith DM, et al.Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228)[J]. J Clin Oncol, 2014, 32(15 Suppl): 3589.
[41] Malka D, Verret B, Faron M, et al.Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: a multicenter phaseⅡ trial[J]. Eur J Cancer, 2023, 195: 113400.
[42] Power DG, Healey-Bird BR, Kemeny NE.Regional chemotherapy for liver-limited metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2008, 7(4): 247-259.
[43] Ducreux M, Ychou M, Laplanche A, et al.Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer[J]. J Clin Oncol, 2005, 23(22): 4881-4887.
[44] Zhao J, Zheng Y, Liu T, et al.Comparison between fluoropyrimidine-hepatic arterial infusion and systemic chemotherapy for unresectable liver metastases: a protocol for systematic review and Meta-analysis based on 16 observational studies[J]. Medicine (Baltimore), 2021, 100(41): e27483.
[45] Cercek A, Boucher TM, Gluskin JS, et al.Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies[J]. J Surg Oncol, 2016, 114(6): 655-663.
[46] Mancuso A, Giuliani R, Accettura C, et al.Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer[J]. Anticancer Res, 2003, 23(2C): 1917-22.
[47] Fiorentini G, Rossi S, Dentico P, et al.Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase Ⅰ-Ⅱ clinical study[J]. Anticancer Res, 2004, 24(3b): 2093-2096.
[48] Feng AW, Guo JH, Gao S, et al.A randomized phaseⅡ trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases[J]. Front Oncol, 2022, 12: 913017.
[49] Boige V, Malka D, Elias D, et al.Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure[J]. Ann Surg Oncol, 2008, 15(1): 219-226.
[50] Ishii M, Itano O, Iwamoto H, et al.Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: a retrospective cohort study[J]. PLoS One, 2025, 20(11): e0336230.
[51] Cao G, Wang X, Chen H, et al.Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study[J]. BMC Gastroenterol, 2022, 22(1): 328.
[52] Zheng K, Zhu X, Xu L, et al.Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy[J]. Front Oncol, 2024, 14: 1420956.
[53] Wang L, Zhang T, Pan Q, et al.A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: an updated analysis of survival[J]. J Clin Oncol, 2024, 42(16 Suppl): 3543-3543.
[54] Lygidakis NJ, Ziras N, Parissis J.Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem[J]. Hepatogastroenterology, 1995, 42(2): 155-161.
[55] Lorenz M, Muller HH, Schramm H, et al.Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)[J]. Ann Surg, 1998, 228(6): 756-762.
[56] Kemeny MM, Adak S, Gray B, et al.Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study[J]. J Clin Oncol, 2002, 20(6): 1499-1505.
[57] Kusano M, Honda M, Okabayashi K, et al.Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003[J]. J Cancer Res Ther, 2017, 13(1): 84-90.
[58] Kemeny N, Daly J, Reichman B, et al.Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial[J]. Ann Intern Med, 1987, 107(4): 459-465.
[59] Chang AE, Schneider PD, Sugarbaker PH, et al.A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases[J]. Ann Surg, 1987, 206(6): 685-693.
[60] Hohn DC, Stagg RJ, Friedman MA, et al.A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial[J]. J Clin Oncol, 1989, 7(11): 1646-1654.
[61] Martin JK, Jr., O'connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial[J]. Arch Surg, 1990, 125(8): 1022-1027.
[62] Rougier P, Laplanche A, Huguier M, et al.Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial[J]. J Clin Oncol, 1992, 10(7): 1112-1118.
[63] Lorenz M, Muller HH.Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma[J]. J Clin Oncol, 2000, 18(2): 243-254.
[64] Kerr DJ, Mcardle CS, Ledermann J, et al.Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial[J]. Lancet, 2003, 361(9355): 368-373.
[65] Li X, Shi L, Wu J, et al.First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases[J]. Cancer Biol Ther, 2016, 17(1): 14-19.
[66] Ito K, Ito H, Kemeny NE, et al.Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors[J]. Ann Surg Oncol, 2012, 19(5): 1609-1617.
[67] Kemeny N, Seiter K, Niedzwiecki D, et al.A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer[J]. Cancer, 1992, 69(2): 327-334.
[68] Neyns B, Van Nieuwenhove Y, Aerts M, et al.Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases[J]. Anticancer Res, 2006, 26(1B): 611-619.
[69] Barnett KT, Malafa MP.Complications of hepatic artery infusion: a review of 4580 reported cases[J]. Int J Gastrointest Cancer, 2001, 30(3): 147-160.
[70] Karanicolas PJ, Metrakos P, Chan K, et al.Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement[J]. Curr Oncol, 2014, 21(1): e129-e136.
[71] Ensminger WD, Rosowsky A, Raso V, et al.A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil[J]. Cancer Res, 1978, 38(11 Pt 1): 3784-3792.
[72] Ranieri G, Laforgia M, Nardulli P, et al.Oxaliplatin-based intra-arterial chemotherapy in colo-rectal cancer liver metastases: a review from pharmacology to clinical application[J]. Cancers (Basel), 2019, 11(2): 141.